Advertisement
Dr. Robert Mattaliano, Group Vice President of Therapeutic Protein R&Dcommented: "The Arecor technology has a demonstrated potential tosignificantly improve the stability of complex biologicals by using novelformulation design principles. Genzyme is pleased to establish this strategicpartnership in support of our goal to provide stable and convenient dosageforms to patients and their caregivers."
Advertisement
Tom Saylor, CEO of Arecor said: "Formulation of the next generation ofbiologics represents unique challenges to developers. Arecor has developed astrong partnership with Genzyme and is privileged to work closely with one ofthe world leaders in biotechnology to help enable new protein-basedtherapeutics."
Arecor Limited was established to provide formulation solutions topharmaceutical and biotech companies developing drugs, vaccines, medicaldevices and diagnostics. Proteins and vaccines are often fragile entities,and stability can represent significant constraints in the development of newproducts and extending the use of existing products. Arecor has developedArestat(TM), a patented set of tools for stabilization, to enable thepresentation of labile biologicals as stable aqueous formulations even athigh concentrations or in situations where cold storage is not practical ordesirable. Arestat(TM) can also protect proteins from degradation in thepresence of ionizing radiation typically used in the sterilization of medicaldevices. As a simple reformulation, Arestat(TM) can be readily incorporatedinto standard manufacturing practice, without covalent medication of thebiological and using excipients approved for the route of delivery. Arecorcurrently has active feasibility programs and licenses with many of the toppharmaceutical and biotech companies on a wide range of proteins and vaccines.Contact: Tom Saylor Phone: +44-1223-426060 Email: [email protected]
SOURCE Arecor
